文献速递腹部技术与安全US

动态超声造影在非肝硬化肝脏肝细胞癌与肝内胆管癌鉴别诊断中的应用

Applications of Dynamic Contrast-Enhanced Ultrasound in Differential Diagnosis of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma in Non-cirrhotic Liver.
PubMed 文献 · Ultrasound Med Biol · 2023-05-06

回顾性纳入非肝硬化肝脏经病理证实的ICC 30例与HCC 24例,术前1周内行CEUS及VueBox定量分析;ICC以环状高增强和动脉期廓清为主,HCC均为不均匀高增强;全部显著定量参数联合鉴别ICC与HCC的AUROC为0.946,敏感度86.7%、特异度95.8%、准确率90.7%,优于CEUS的58.3%、90.0%、75.9%。

要点

  • 非肝硬化肝脏ICC动脉期以环状高增强(50.0%)和不均匀高增强(43.3%)为主,HCC全部为不均匀高增强(100.0%)。
  • ICC多数动脉期廓清(83.3%),HCC动脉期与门静脉期廓清各占41.7%,仅16.7%延迟期廓清。
  • DCE-US定量参数联合鉴别非肝硬化肝脏ICC与HCC的AUROC为0.946,敏感度86.7%、特异度95.8%、准确率90.7%。

核心结论

  • 非肝硬化肝脏ICC与HCC的CEUS特征可能存在重叠,DCE-US定量分析有助于术前鉴别诊断。

研究设计与样本

  • 回顾性研究,纳入2020年11月至2022年2月病理证实的非肝硬化肝脏ICC 30例和HCC 24例,术前1周内使用Acuson Sequoia或LOGIQ E20行CEUS,造影剂为SonoVue,VueBox软件定量分析。

关键影像表现/征象

  • 动脉期ICC表现为不均匀高增强13/30(43.3%)、不均匀低增强2/30(6.7%)、环状高增强15/30(50.0%),HCC全部为不均匀高增强24/24(100.0%)(p < 0.05)。
  • ICC廓清见于动脉期25/30(83.3%)和门静脉期5/30(15.7%),HCC廓清见于动脉期10/24(41.7%)、门静脉期10/24(41.7%)和延迟期4/24(16.7%)(p < 0.05)。
  • 与HCC相比,ICC的时间-强度曲线显示动脉期增强更早且更低、门静脉期下降更快、曲线下面积减小。

诊断标准与关键数值

  • 全部显著定量参数联合鉴别非肝硬化肝脏ICC与HCC的AUROC为0.946,敏感度86.7%、特异度95.8%、准确率90.7%。
  • CEUS鉴别非肝硬化肝脏ICC与HCC的敏感度58.3%、特异度90.0%、准确率75.9%。

临床应用与阅片要点

  • 术前CEUS动脉期环状高增强及动脉期廓清提示ICC可能,不均匀高增强伴门静脉期或延迟期廓清提示HCC可能。
  • DCE-US定量参数联合分析可提高非肝硬化肝脏ICC与HCC的鉴别效能,可结合TIC形态与定量参数综合判断。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The aim of the work described here was to investigate the value of dynamic contrast enhanced ultrasound (DCE-US) and quantitative analysis in pre-operative differential diagnosis of intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) in non-cirrhotic liver.

METHODS: In this retrospective study, patients with histopathologically proven ICC and HCC lesions in non-cirrhotic liver were included. All patients underwent contrast-enhanced ultrasound (CEUS) examinations with an Acuson Sequoia unit (Siemens Healthineers, Mountain View, CA, USA) unit or LOGIQ E20 (GE Healthcare, Milwaukee, WI, USA) within 1 wk before surgery. SonoVue (Bracco, Milan, Italy) was used as the contrast agent. B-mode ultrasound (BMUS) features and CEUS enhancement patterns were analyzed. DCE-US analysis was performed by VueBox software (Bracco). Two regions of interest (ROIs) were set in the center of the focal liver lesions and their surrounding liver parenchyma. Time-intensity curves (TICs) were generated, and quantitative perfusion parameters were obtained and compared between the ICC and HCC groups using the Student t-test or Mann-Whitney U-test.

RESULTS: From November 2020 to February 2022, patients with histopathologically confirmed ICC (n = 30) and HCC (n = 24) lesions in non-cirrhotic liver were included. During the arterial phase (AP) of CEUS, ICC lesions exhibited heterogeneous hyperenhancement (13/30, 43.3%), heterogeneous hypo-enhancement (2/30, 6.7 %) and rim-like hyperenhancement (15/30, 50.0%), whereas all HCC lesions exhibited heterogeneous hyperenhancement (24/24, 100.0%) (p < 0.05). Subsequently, most of the ICC lesions exhibited AP wash-out (83.3%, 25/30), whereas a few cases exhibited wash-out in the portal venous phase (PVP) (15.7%, 5/30). In contrast, HCC lesions exhibited AP wash-out (41.7%, 10/24), PVP wash-out (41.7%, 10/24) and a small part of late phase wash-out (16.7%, 4/24) (p < 0.05). Compared with those of HCC lesions, TICs of ICCs revealed earlier and lower enhancement during the AP, faster decline during the PVP and reduced area under the curve. The combined area under the receiver operating characteristic curve (AUROC) of all significant parameters was 0.946, with 86.7% sensitivity, 95.8% specificity and 90.7% accuracy in differential diagnosis between ICC and HCC lesions in non-cirrhotic liver, which improved the diagnostic efficacy of CEUS (58.3% sensitivity, 90.0% specificity and 75.9% accuracy).

CONCLUSION: ICC and HCC lesions in non-cirrhotic liver might exhibit some overlap of CEUS features in diagnosis. DCE-US with quantitative analysis would be helpful in pre-operative differential diagnosis.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Dong, Chen, Möller, et al. Applications of Dynamic Contrast-Enhanced Ultrasound in Differential Diagnosis of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma in Non-cirrhotic Liver. Ultrasound Med Biol. 2023. PMID: 37156676. doi:10.1016/j.ultrasmedbio.2023.03.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。